National Systemic Anti-Cancer Therapy (SACT) consent forms – forms for melanoma regimens and generic immunotherapy form published
The regimen-specific consent forms for melanoma and a generic form for immunotherapy have been published on the Cancer Research UK (CRUK) website. There are 13 forms for melanoma:
- Carboplatin
- Cobimetinib-Vemurafenib
- CVD (cisplatin-vinblastine-dacarbazine)
- Dabrafenib
- Dabrafenib-Trametinib
- Dacarbazine
- Ipilimumab
- Ipilimumab-Nivolumab
- Nivolumab
- Pembrolizumab
- Talimogene laherparepvec (Imlyglic®)
- Temozolomide
- Vemurafenib
Please visit www.cruk.org/sact_consent to view and download the forms. Other forms, national guidance on consent for SACT, and further information is also available via www.cruk.org/sact_consent.
The National Chemotherapy Board published guidance on consent for SACT in July 2016 and recommends use of the regimen-specific forms in the UK. The forms have been produced with support from CRUK.
Please do not hesitate to contact Rena Chauhan (Oncology Pharmacist – CRUK information lead, Guy’s and St. Thomas’ NHS Foundation Trust) if you have any queries: [email protected].
Rena Chauhan
14th December 2016
